

1 **Early transfusion of a large cohort of COVID-19 patients with high titer anti-**
2 **SARS-CoV-2 spike protein IgG convalescent plasma confirms a signal of**
3 **significantly decreased mortality**

4
5 **Eric Salazar^{a,b}, Paul A. Christensen^a, Edward A. Graviss^{a,c}, Duc T. Nguyen^c, Brian Castillo^a, Jian**
6 **Chen^a, Bevin Valdez Lopez^d, Todd N. Eagar^{a,b}, Xin Yi^{a,b}, Picheng Zhao^a, John Rogers^a, Ahmed**
7 **Shehabeldin^a, David Joseph^a, Faisal Masud^e, Christopher Leveque^a, Randall J. Olsen^{a,b,c}, David**
8 **W. Bernard^{a,b}, Jimmy Gollihar^f, and James M. Musser^{a,b,c,#}**

9
10 ^aDepartment of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas

11 ^bDepartment of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New
12 York

13 ^cCenter for Molecular and Translational Human Infectious Diseases, Houston Methodist Research
14 Institute, Houston, Texas

15 ^dAcademic Office of Clinical Trials, Houston Methodist Research Institute, Houston, Texas

16 ^eDepartment of Anesthesiology and Critical Care, Houston Methodist Hospital, Houston, Texas

17 ^fCCDC Army Research Laboratory-South, University of Texas at Austin, Austin, Texas

18

19 Number of text pages, tables, and figures: 12 text pages, 4 tables, 5 figures, 4 supplemental tables

20 Short running head: Convalescent plasma efficacy signal

21 Grant numbers and sources of support: This study was supported by the Fondren Foundation, Houston
22 Methodist Hospital and Research Institute (to JMM).

23 Financial Disclosure and Conflicts of Interest: ES is the local principal investigator for a clinical trial
24 sponsored by Regeneron assessing an investigational therapy for COVID-19.

25 **#Corresponding author:**

26 James M. Musser, MD, PhD, 6565 Fannin St., Suite B490, Houston, TX 77030

27 Phone: 713.441.5890, Fax: 713.441.3886, Email: jmmusser@houstonmethodist.org

28

29 **ABSTRACT**

30 Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2
31 remains a global threat with few proven efficacious treatments. Transfusion of convalescent plasma
32 collected from donors who have recovered from COVID-19 disease has emerged as a promising
33 therapy and has been granted emergency use authorization by the U.S. Food and Drug Administration
34 (FDA). We recently reported results from interim analysis of a propensity-score matched study
35 suggesting that early treatment of COVID-19 patients with convalescent plasma containing high titer
36 anti-spike protein receptor binding domain (RBD) IgG significantly decreases mortality. We here
37 present results from 60-day follow up of our cohort of 351 transfused hospitalized patients. Prospective
38 determination of ELISA anti-RBD IgG titer facilitated selection and transfusion of the highest titer units
39 available. Retrospective analysis by the Ortho VITROS IgG assay revealed a median signal/cutoff (S/C)
40 ratio of 24.0 for transfused units, a value far exceeding the recently FDA-required cutoff of 12.0 for
41 designation of high titer convalescent plasma. With respect to altering mortality, our analysis identified
42 an optimal window of 44 hours post-hospitalization for transfusing COVID-19 patients with high titer
43 convalescent plasma. In the aggregate, the analysis confirms and extends our previous preliminary
44 finding that transfusion of COVID-19 patients soon after hospitalization with high titer anti-spike protein
45 RBD IgG present in convalescent plasma significantly reduces mortality.

46

47

48 INTRODUCTION

49 Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2
50 (SARS-CoV-2) has caused massive societal disruption and death globally. As of September 27, 2020,
51 there have been more than 33 million COVID-19 cases causing in excess of 1,000,000 deaths
52 worldwide.¹ The United States has many areas where rising case rates continue to threaten multiple
53 populations. Very few effective treatments exist (<https://www.covid19treatmentguidelines.nih.gov/>),
54 although hundreds of registered clinical trials are ongoing, including several phase 3 vaccine trials
55 (<https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html>, last accessed
56 September 24, 2020).

57 We and others have published safety and efficacy outcomes in patients who were transfused
58 with COVID-19 convalescent plasma.²⁻⁴ Aggregated available evidence stimulated the U.S. Food and
59 Drug Administration (FDA) in late August 2020 to grant Emergency Use Authorization (EUA) for
60 COVID-19 convalescent plasma therapy (<https://www.fda.gov/media/141477/download>, last accessed
61 September 24, 2020). In our previous study, interim analysis revealed that, relative to matched controls,
62 patients transfused with convalescent plasma containing high titer anti-spike protein receptor binding
63 domain (RBD) IgG within 72 hrs of hospital admission had significantly reduced mortality at 28 days
64 post-transfusion.³

65 To further investigate these observations, and to address limitations inherent in an interim
66 analysis, we here present results from 60-day follow up of our entire cohort of 351 transfused patients.
67 The data confirm our previous findings that transfusion of patients soon after hospital admission with
68 high titer anti-spike protein RBD IgG present in convalescent plasma significantly decreases mortality.

69

70 MATERIALS AND METHODS

71 We analyzed data from patients cared for in all eight Houston Methodist hospitals from March 28, 2020,
72 through September 14, 2020, with the approval of the Houston Methodist Research Institute ethics

73 review board and with written informed consent of the patient or legally authorized representative.
74 Details of the study, including inclusion and exclusion criteria, and criteria for the transfusion of multiple
75 units have been described.³

76 *Convalescent plasma donors, antibody titer assessment, and donor unit selection*

77 Detailed protocols for convalescent plasma collection and anti-spike protein titer assessment have
78 been described.^{3, 5, 6} COVID-19 convalescent plasma units were selected for transfusion based on anti-
79 spike ectodomain and RBD IgG ELISA titers available on donor units obtained from April 7, 2020
80 onward. We previously published that plasma with an anti-RBD IgG titer of $\geq 1:1350$ corresponds to an
81 ~80% probability of a live virus *in vitro* neutralization titer of $\geq 1:160$.⁷ This titer is the value initially
82 recommended by the FDA for transfusing COVID-19 patients.⁸ To facilitate the need for increased
83 donor unit assessment, we standardized our ELISA to four plasma dilutions: 1:50, 1:150, 1:450, and
84 1:1350. To select the highest titer unit available, ELISA results were ranked based on highest titer and,
85 subsequently by highest optical density at dilution 1:50. Patients were transfused with the ABO-
86 compatible convalescent plasma unit with the highest titer and highest optical density at dilution 1:50
87 available. Frozen serum samples were assessed retrospectively with the Ortho VITROS IgG assay
88 (Raritan, NJ) according to manufacturer's instructions.

89 *Statistical analysis*

90 We analyzed patients who met a 60-day outcome defined as having outcome data available 60 days
91 post-transfusion (cases) and 60 days post-hospitalization (controls). Control patients enrolled in other
92 clinical trials were excluded from the analysis. Patients discharged before Day 60 were presumed to be
93 on room air after discharge unless otherwise noted in the electronic medical record. Baseline
94 characteristics for COVID-19 patients who met the 60-day outcome definition are shown in **Table S1**.

95 We conducted a one-to-many nearest neighbor propensity score matching analysis without
96 replacement using an initial ratio of case:control=1:3 and caliper of ≤ 1 between patients having plasma
97 transfusion (cases) versus patients who did not have plasma transfusion (controls). The primary

98 matching criteria included age (categorical, <30, 30-39, 40-49, 50-59, 60-69, 70-79, ≥80), sex, BMI (+/-
99 30), diabetes, hypertension, chronic pulmonary disease, chronic kidney disease, hyperlipidemia,
100 coronary disease, and baseline ventilation requirement within 48 hrs of admission, use of any steroid,
101 azithromycin, hydroxychloroquine, remdesivir, ribavirin, and tocilizumab. A secondary propensity score
102 matching was conducted based on the ventilation status at Day 0, defined as the day of transfusion for
103 cases and the corresponding day in the hospitalization course for controls, using a case:control ratio of
104 either 1:2 or 1:1 and caliper ≤ 1 .⁹

105 The primary outcome (mortality within 60 days post-Day 0) was displayed by Kaplan-Meier
106 curves. Differences between groups were compared with the log-rank test. Cox proportional hazards
107 modeling (with clustered sandwich estimator option for the matched cluster in the propensity-matched
108 cohorts) was performed to determine the characteristics associated with the overall mortality within 28
109 days and 60 days. Variables for the multivariable models were selected based on potential clinical
110 relevance and using Stata's Lasso technique with cross-validation.^{10, 11} Receiver operating
111 characteristic (ROC) curve analysis with Youden index was used to identify the optimal time (in hours)
112 from admission-to-transfusion of first unit that discriminates 60-day mortality in patients that received
113 COVID-19 convalescent plasma.¹²

114 Generalized linear modeling (GLM) and multinomial logistic regression with a cluster variance
115 estimator were also used to evaluate several exploratory endpoints. The evaluated covariates included
116 supplemental oxygen requirements (room air, low-flow oxygen delivery, high-flow oxygen delivery, non-
117 invasive positive pressure ventilation, mechanical ventilation, extracorporeal membrane oxygenation
118 (ECMO), or death) at Day 7, Day 14, Day 28, and Day 60 post-transfusion; clinical improvement
119 relative to Day 0; intensive care unit (ICU) stay requirement; ICU length of stay; mechanical ventilation
120 requirement; length of mechanical ventilation requirement; length of supplemental oxygen requirement;
121 and inflammatory marker levels (interleukin-6, C-reactive protein, ferritin, fibrinogen, D-dimer) at Day 7.
122 Clinical improvement relative to Day 0 was defined as a 1 point improvement in ordinal scale [1,
123 discharged (alive); 2, hospitalized, not requiring supplemental oxygen but requiring ongoing medical
124 care (for COVID-19 or otherwise); 3, hospitalized, requiring low-flow supplemental oxygen; 4,

125 hospitalized, on non-invasive ventilation or high-flow oxygen devices; 5, hospitalized and on invasive
126 mechanical ventilation or ECMO; 6, death]. All analyses were performed with Stata version 16.1
127 (StataCorp LLC, College Station, TX, USA) or the R Statistical Computing environment ([http://www.R-](http://www.R-project.org/)
128 [project.org/](http://www.R-project.org/)). A p -value of ≤ 0.05 was considered significant.

129

130 **RESULTS**

131 *Study population and baseline characteristics*

132 We had 5,297 hospitalized COVID-19 patients available for analysis, 353 of whom were transfused with
133 COVID-19 convalescent plasma. Two of the 353 patients received plasma without a titer assessment
134 prior to transfusion, and these patients were excluded from the overall analysis, resulting in a cohort of
135 351 transfused evaluable patients. Relative to non-transfused patients, transfused patients were
136 significantly younger, predominantly male, predominantly Hispanic, had a higher BMI, lower rates of
137 comorbidities (specifically, chronic pulmonary disease, chronic kidney disease, hyperlipidemia, and
138 coronary disease, but not hypertension and diabetes), a higher requirement for supplemental oxygen,
139 and higher inflammatory biomarker concentrations. D-dimer was significantly lower in the transfused
140 cohort at baseline by 0.2 fibrinogen equivalent units. Use of steroids, azithromycin, remdesivir, and
141 tocilizumab was more common among the transfused cohort (**Table S1**).

142 *Safety*

143 Among 351 transfused patients included in the study, only seven (2.0%) had adverse events deemed
144 related to plasma transfusion. Six events were classified as allergic transfusion reactions and five of
145 these six were mild and included only a transient rash. One patient developed transient worsening of
146 shortness of breath that resolved with diphenhydramine. One case of possible transfusion-associated
147 circulatory overload occurred, with associated transient worsening of dyspnea that improved with
148 furosemide. These two events were deemed to be significant adverse events. Thus, among the 351
149 transfused study patients, only two (0.6%) significant adverse events were deemed related to plasma
150 transfusion.

151 *Factors associated with a higher risk of death in all hospitalized COVID-19 patients*

152 Univariate and multivariate Cox proportional hazards modeling assessing factors associated with a
153 higher risk of death within 60 days post-transfusion Day 0 was performed for all COVID-19 patients
154 admitted to our eight hospitals during the study period for whom data were available (**Tables S2 and**
155 **S3**). Factors associated with a higher risk of death in the multivariate analysis included age, male sex,
156 diabetes, chronic kidney disease, worst ventilation status within 48 hrs of admission, and/or
157 administration of any steroids or tocilizumab. Neither ABO blood type, race, nor ethnicity were
158 associated with higher risk of death in the multivariate analysis. Importantly, the covariates that had a
159 significant association with risk of death were included in the propensity score matching algorithm. We
160 did not include baseline inflammatory concentrations in the multivariate analysis and in the propensity
161 score matching algorithm because of the high proportion of missing data.

162 *COVID-19 convalescent plasma and retrospective analysis of Ortho VITROS IgG test data*

163 Most transfused patients (278/351; 79%) received only one ~300 mL unit of COVID-19 convalescent
164 plasma. The great majority of patients received an initial or sole unit of convalescent plasma with anti-
165 RBD IgG titer of $\geq 1:1350$ (321/351; 91%); 24 patients received an initial or sole unit of convalescent
166 plasma with an anti-RBD IgG titer $>1:150$ but $<1:1350$; six patients received an initial or sole unit of
167 convalescent plasma with anti-RBD IgG titer of $<1:150$. For patients who received a second unit of
168 convalescent plasma, 71 (71/75; 95%) received a second unit with an anti-RBD IgG titer $\geq 1:1350$, and
169 four (4/75; 5%) patients received a second unit with an anti-RBD IgG titer $>1:150$ but $<1:1350$.

170 The FDA issued an EUA for convalescent plasma transfusion of COVID-19 patients on August
171 23, 2020. The agency's guidance is to use convalescent plasma units with an S/C level of >12 , as
172 defined by the Ortho VITROS IgG test (<https://www.fda.gov/media/141477/download>, last accessed
173 September 24, 2020). For 278 of the 351 (79%) initial plasma units transfused, a sample was available
174 for retrospective assessment of anti-SARS-CoV-2 IgG titer by the Ortho VITROS IgG test. The median
175 IgG signal/cutoff (S/C) ratio was 24.0 (range=0.01-35) and only seven units (3%) had a corresponding
176 S/C ratio of <12 . In addition, we found a very strong positive correlation between the ELISA anti-RBD

177 IgG optical density at dilution 1:50 and the Ortho VITROS IgG test for 1,142 samples with parallel
178 assessment ($R=0.88$; $P<0.001$). The distribution of Ortho VITROS IgG S/C ratios and anti-RBD IgG
179 ELISA optical density for transfused plasma units confirms that high anti-spike protein IgG titer units
180 were being given to the enrolled COVID-19 patients (**Figure 1**).

181 *Outcomes*

182 Propensity score matching yielded a study population of 341 transfused patients and 594 matched
183 controls, which were balanced across all matching criteria (**Figure 2 and Table S4**). Kaplan-Meier
184 curves showed significantly decreased mortality within 60 days post-Day 0 in the transfused cohort
185 relative to propensity score-matched controls ($P=0.02$) (data not shown). Statistical significance
186 increased to $P=0.003$ when the matching algorithm and analysis were restricted to patients transfused
187 with plasma with an anti-RBD IgG titer of $\geq 1:1350$ (**Figure 3**). Mortality was not significantly different
188 within 60 days post-Day 0 between cases and controls in patients who were intubated at Day 0 or in
189 patients who were transfused more than 72 hrs after admission, even when the analysis was restricted
190 to patients who received plasma with a high titer anti-RBD IgG. There was no significant difference in
191 mortality between cases and controls when the analysis was restricted to patients who received plasma
192 with an anti-RBD IgG titer of $< 1:1350$. In contrast, mortality was significantly decreased in patients who
193 received plasma with an anti-RBD IgG titer of $\geq 1:1350$ within 72 hrs of admission (**Figure 4**). Point
194 estimates of the outcomes when the analysis was restricted to transfusion of high titer plasma confirm
195 these findings (**Table 1**).

196 Consistent with these observations, the unadjusted HR and adjusted HR in the univariate and
197 multivariate Cox proportional hazards models for mortality within 60 days was significant when the
198 analysis was restricted to patients who received plasma with an anti-RBD IgG titer of $\geq 1:1350$ (**Table**
199 **2**). Due to small sample sizes, multivariate analysis could not be performed for patients who received
200 plasma with a titer $\geq 1:1350$ and were intubated at Day 0, or who were transfused more than 72 hrs after
201 hospitalization. In these two cohorts, the unadjusted HR in univariate analyses for mortality within 60
202 days post-Day 0 was not significant (HR=1.61 for controls; $P=0.44$ and HR=1.93 for controls; $P=0.16$,

203 respectively). Similarly, the unadjusted HR for mortality within 60 days in the analysis restricted to
204 patients who received plasma with a titer <1:1350 was not significant (HR=1.57 for controls, $P=0.36$).
205 However, the unadjusted HR for mortality within 60 days was significant (HR=1.93 for controls, $P=0.02$)
206 when the analysis was restricted to patients who received plasma with a titer $\geq 1:1350$ within 72 hrs of
207 hospital admission. For this cohort, the adjusted HR for mortality within 60 days was significant when
208 assessed for a 28-day outcome (aHR=2.09 for controls; $P=0.047$) and approached significance when
209 assessed for a 60-day outcome (aHR=1.82 for controls; $P=0.051$).

210 We sought to identify the optimal window after hospitalization within which transfusion of
211 convalescent plasma was most useful with respect to altering mortality. ROC curve analysis with
212 Youden index revealed an optimal cut point of transfusion within 44 hrs of hospital admission for
213 discriminating mortality within 60 days post-transfusion in all patients transfused with COVID-19
214 convalescent plasma (**Figure 5A**). The analysis identified the same cut point when restricted to patients
215 transfused with convalescent plasma with an anti-RBD IgG titer $\geq 1:1350$. Therefore, we performed the
216 propensity score-matched analysis using this cut point as a restrictor. Cohorts were again balanced
217 across all matching criteria (data not shown). The resulting Kaplan-Meier curves showed significantly
218 decreased mortality within 60 days post-Day 0 in the cohort transfused with convalescent plasma with
219 an anti-RBD IgG $\geq 1:1350$ within 44 hrs of admission relative to propensity score-matched controls
220 ($P=0.004$) (**Figure 5B**). Point estimates of the outcomes for the analysis restricted to transfusion of high
221 titer convalescent plasma within 44 hrs confirm these findings (**Table 3**). Univariate Cox regression in
222 this cohort revealed a significant unadjusted HR for mortality within 60 days (HR=3.26 for controls,
223 $P=0.01$). Likewise, multivariate Cox regression showed a significant adjusted HR for mortality within 28
224 days (aHR=2.63 for controls, $P=0.04$) and within 60 days post-Day 0 (aHR = 2.90 for controls, $P=0.02$)
225 (**Table 4**).

226

227 DISCUSSION

228 Transfusion of convalescent plasma has emerged in the last six months as a promising therapy for
229 COVID-19 patients and has been granted emergency use authorization for hospitalized patients by the

230 FDA. Because of the logistical challenges of planning and executing a study during a rapidly changing
231 pandemic involving very complex medical patients, the results of few completed controlled studies
232 assessing convalescent plasma efficacy have been published. Here, we provide an analysis of a
233 propensity score-matched study from a large cohort of hospitalized COVID-19 patients who were
234 transfused in one healthcare system with high-titer convalescent plasma qualified in one laboratory. In
235 the aggregate, the data confirm and extend findings from our interim analysis suggesting that
236 transfusion of convalescent plasma with high titer anti-RBD IgG is safe and significantly decreases
237 COVID-19 mortality.³ Transfusion later in hospitalization or later in the disease course (e.g., post-
238 intubation) had no significant benefit on mortality, regardless of plasma titer. Several lines of evidence
239 support our findings, including survival analyses of specific cohorts of transfused patients relative to
240 matched controls, point estimates from the generalized linear model and multinomial logistic
241 regression, and univariate and multivariate analyses.

242 The current analysis addressed several limitations we identified in our interim analysis.³ First,
243 the patient sample size is almost three times as large as that included in our interim analysis. Second,
244 we included additional covariates in the propensity score matching algorithm, including relevant
245 concomitant medications (any steroid, azithromycin, hydroxychloroquine, remdesivir, ribavirin, and
246 tocilizumab). Importantly, factors identified as having a significant adjusted HR for mortality for all
247 hospitalized COVID-19 patients were included in the propensity match. Third, because a large
248 proportion of deaths occurred after 28 days post-Day 0, we assessed a 60-day outcome. Fourth,
249 control patients enrolled in other clinical trials involving alternative experimental therapies were
250 excluded. Fifth, when possible, we performed multivariate analyses assessing factors associated with
251 mortality within 60 days. Finally, we used ROC analysis with Youden index to identify the optimal cut
252 point at which transfusion of convalescent plasma is most useful with respect to altering mortality.

253 Our results bear on other recent studies treating patients with convalescent plasma.^{4, 9, 13-16} For
254 example, a recent fixed-effect meta-analysis model assessing 12 controlled studies of COVID-19
255 convalescent plasma found that the aggregate mortality rate of transfused COVID-19 patients was

256 significantly lower than that of non-transfused patients.⁴ Results from three randomized controlled
257 studies and one large observational study have recently been released.^{2, 17-19} The PLACID trial found
258 convalescent plasma was not associated with significantly reduced mortality or progression to severe
259 disease.¹⁷ However, resolution of shortness of breath, fatigue, and negative conversion of SARS-CoV-2
260 viral RNA at Day 7 was higher in the transfused study arm. The authors acknowledged several
261 limitations of their study. For example, the proportion of patients with comorbidities, especially diabetes,
262 was higher in the transfused study arm. Importantly, most of the convalescent plasma donors were
263 young with mild disease and their median titer of neutralizing antibody was 1:40, a value considerably
264 lower than the FDA-recommended neutralizing antibody titer of 1:160. In addition, neutralizing antibody
265 titers were not determined before transfusion, which means the highest titer units were not used for
266 transfusion. Similar results were reported for a randomized controlled trial conducted in Chile in which
267 neutralizing antibody titers in donor plasma were not determined prior to transfusion.¹⁹ In contrast,
268 interim analysis of a randomized controlled trial from Spain with 81 randomized patients, reported that
269 no patients progressed to mechanical ventilation or death among the 38 patients receiving
270 convalescent plasma (0%), whereas six of 43 patients (14%) in the control arm did.¹⁸ Mortality rates
271 were 0% versus 9.3% at Days 15 and 29 for the active and control groups, respectively. All transfused
272 convalescent plasma units had neutralizing antibodies with a titer >1:80 with a median titer of 1:292.
273 Unfortunately, the trial was stopped after the first interim analysis due to decreased recruitment related
274 to better control of the pandemic. In contrast to several of the studies cited above, we methodically
275 selected units for transfusion based on the ELISA data identifying the highest level of IgG antibody
276 directed against spike ectodomain and RBD. We transfused compatible donor units determined to have
277 the highest antibody titer available, an approach confirmed by our retrospective assessment of anti-
278 SARS-CoV-2 IgG by the Ortho VITROS assay (**Figure 1**). Thus, the vast majority of our patients were
279 transfused with convalescent plasma units with very high titer anti-spike protein IgG. We think it
280 reasonable to speculate that this strategy contributed to differences in outcomes observed between our
281 study and several others that did not transfuse patients with plasma units specifically chosen to have
282 very high IgG antibody levels against spike protein. Overall, the results from various published studies

283 highlight the difficulty in drawing definitive conclusions for convalescent plasma efficacy from multiple
284 studies with variable design, a problem that can extend to and thereby hobble randomized controlled
285 trials with different study designs.

286 Substantial efforts to collect, use, and study COVID-19 convalescent plasma continue
287 worldwide. Our study has several implications for these efforts. The data presented here may inform
288 the design and conduct of ongoing or future studies. For example, we conclude that transfusing plasma
289 units with low or no antibody titer against spike protein is unlikely to be beneficial. Our data support the
290 concept that assessment of antibody titer by either a viral neutralization assay or a surrogate thereof
291 prior to transfusion is essential, regardless of the type of trial being conducted. In addition, transfusing
292 relatively soon after hospitalization will be more beneficial than the alternative. Our finding that a large
293 proportion of deaths in COVID-19 patients occurs after Day 28 may also have implications for study
294 design, as findings at Day 28 may not apply over a longer follow-up period.

295 Importantly, our study has several limitations. First, it is a propensity score-matched study rather
296 than a randomized controlled trial. Although we made every effort to control for all important covariates,
297 potentially relevant covariates may have been omitted unintentionally from the matching algorithm.
298 Second, the background standard of care for COVID-19 has evolved as new data emerged. Thus, we
299 may not have completely addressed the potential for variations over time in background standard of
300 care and period effect as sources of confounding in our dataset. Third, there was heterogeneity in the
301 transfusion of two units versus one based on inventory limitations early in the study and on patient
302 enrollment in other trials that specifically excluded redosing of convalescent plasma. Fourth, our
303 analysis was based on patient data available in the electronic medical record. Fifth, we note that the
304 results reflect the experience of one system of eight hospitals in the Houston metropolitan region that
305 have a fairly uniform approach to COVID-19 patient care. Our findings may not apply to all hospitalized
306 COVID-19 patients because of inter-institutional and/or regional heterogeneity in medical care. Sixth,
307 baseline inflammatory marker measurements were not included in the matching algorithm due to the
308 high proportion of missing data points. Our study approach facilitated rapid assessment of safety and
309 efficacy of high-titer anti-SARS-CoV-2 convalescent plasma transfusion during early phases of a rapidly

310 evolving pandemic with uncertain trajectory. The data presented here may help to inform the science
311 and logistics of ongoing and future studies that address the use of convalescent plasma for other
312 emerging and rapidly disseminating infectious diseases.

313 To summarize, this propensity score-matched analysis of a large patient cohort confirms and
314 extends our previous findings and suggests that transfusion of convalescent plasma containing very
315 high titer anti-RBD IgG early in hospitalization reduces mortality in COVID-19 patients.

316

317 **ACKNOWLEDGMENTS**

318 We are deeply indebted to all of our volunteer plasma donors for their time, their generous gift, and
319 their solidarity. We thank Katharine G. Dlouhy, Curt Hampton, and their team of coordinators and
320 recruiters for outstanding efforts; Monisha Dey, Cheryl Chavez-East, who were instrumental in
321 efficiently managing the donor center; Kate Cody, Sayali Kelkar, Belimat Askary, and the clinical
322 analytics team for their assistance with data acquisition and management; Drs. Jessica Thomas and
323 Zejuan Li, Erika Walker, the very talented and dedicated molecular technologists, and the many labor
324 pool volunteers in the Molecular Diagnostics Laboratory for their dedication to patient care; the many
325 donor center and blood bank phlebotomists and technologists for their dedication to donor and blood
326 safety; Sasha Pejerrey, Adrienne Winston, and Heather McConnell for editorial assistance; Claude
327 Moussa, Heather Patton, and other members of our laboratory information technology team for rapidly
328 implementing the necessary electronic workflows; Pamela McShane, Dilzi Mody, and members of the
329 biorepository team for their meticulous management of patient samples; Christina Talley, Susan Miller,
330 and Mary Clancy for consistent, thorough, and outstanding advice; and Zivko Nikolov, Susan Woodard,
331 and Michael Johanson at the National Center for Therapeutics Manufacturing at Texas A&M University
332 for production of spike protein antigens. We express our gratitude to Manuel Hinojosa and Mark
333 Vassallo for their extensive efforts to rapidly procure resources. We are indebted to Drs. Marc Boom
334 and Dirk Sostman for their support, and to many very generous Houston citizens and businesses for
335 their tremendous philanthropic support of this ongoing project, including but not limited to anonymous,

336 Ann and John Bookout III, Carolyn and John Bookout, Ting Tsung and Wei Fong Chao Foundation,
337 Ann and Leslie Doggett, Freeport LNG, the Hearst Foundations, Jerold B. Katz Foundation, C. James
338 and Carole Walter Looke, Diane and David Modesett, the Sherman Foundation, Paula and Joseph C.
339 “Rusty” Walter III, and Aramco Americas. Dr. Jason S. McLellan (University of Texas at Austin)
340 provided the mAb CR3022 and the spike protein expression vectors, and we thank the members of the
341 Center for Systems and Synthetic Biology at the University of Texas at Austin for technical assistance.
342 We thank Terumo BCT for continuously and rapidly supplying blood collection devices and supplies.
343 We also thank Shmuel Shoham, MD for graciously sharing a draft study protocol for adaptation early in
344 the study planning phase.

345

346 Statement of ethical assurance: JMM is the guarantor of this work and, as such, had full access to all of
347 the data in the study and takes responsibility for the integrity of the data and the accuracy of the data
348 analysis.

349

350

351 **REFERENCES**

- 352 [1] COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns
353 Hopkins University (JHU). Johns Hopkins University and Medicine, 2020.
- 354 [2] Joyner MJ, Senefeld JW, Klassen SA, Mills JR, Johnson PW, Theel ES, Wiggins CC, Bruno KA,
355 Klompas AM, Lesser ER, Kunze KL, Sexton MA, Diaz Soto JC, Baker SE, Shepherd JRA, van
356 Helmond N, van Buskirk CM, Winters JL, Stubbs JR, Rea RF, Hodge DO, Herasevich V, Whelan ER,
357 Clayburn AJ, Larson KF, Ripoll JG, Andersen KJ, Buras MR, Vogt MNP, Dennis JJ, Regimbal RJ,
358 Bauer PR, Blair JE, Paneth NS, Fairweather D, Wright RS, Carter RE, Casadevall A: Effect of
359 Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month
360 Experience. medRxiv 2020.
- 361 [3] Salazar E, Christensen PA, Graviss EA, Nguyen DT, Castillo B, Chen J, Lopez BV, Eagar TN, Yi X,
362 Zhao P, Rogers J, Shehabeldin A, Joseph D, Leveque C, Olsen RJ, Bernard DW, Gollihar J, Musser
363 JM: Treatment of Coronavirus Disease 2019 Patients with Convalescent Plasma Reveals a Signal of
364 Significantly Decreased Mortality. Am J Pathol 2020.
- 365 [4] Joyner MJ, Klassen SA, Senefeld J, Johnson PW, Carter RE, Wiggins CC, Shoham S, Grossman
366 BJ, Henderson JP, Musser JM, Salazar E, Hartman WR, Bouvier NM, Liu STH, Pirofski L-a, Baker SE,
367 Van Helmond N, Wright RS, Fairweather D, Bruno KA, Paneth NS, Casadevall A: Evidence favouring
368 the efficacy of convalescent plasma for COVID-19 therapy. medRxiv 2020:2020.07.29.20162917.
- 369 [5] Salazar E, Kuchipudi SV, Christensen PA, Eagar TN, Yi X, Zhao P, Jin Z, Long SW, Olsen RJ, Chen
370 J, Castillo B, Leveque C, Towers DM, Lavinder J, Gollihar JD, Cardona J, Ippolito GC, Nissly RH, Bird
371 IM, Greenawalt D, Rossi RM, Gontu A, Srinivasan S, Poojary IB, Cattadori IM, Hudson PJ, Joselyn N,
372 Prugar L, Huie K, Herbert A, Bernard DW, Dye J, Kapur V, Musser JM: Relationship between Anti-
373 Spike Protein Antibody Titers and SARS-CoV-2 In Vitro Virus Neutralization in Convalescent Plasma.
374 bioRxiv 2020.
- 375 [6] Salazar E, Perez KK, Ashraf M, Chen J, Castillo B, Christensen PA, Eubank T, Bernard DW, Eagar
376 TN, Long SW, Subedi S, Olsen RJ, Leveque C, Schwartz MR, Dey M, Chavez-East C, Rogers J,
377 Shehabeldin A, Joseph D, Williams G, Thomas K, Masud F, Talley C, Dlouhy KG, Lopez BV, Hampton

- 378 C, Lavinder J, Gollihar JD, Maranhao AC, Ippolito GC, Saavedra MO, Cantu CC, Yerramilli P, Pruitt L,
379 Musser JM: Treatment of Coronavirus Disease 2019 (COVID-19) Patients with Convalescent Plasma.
380 Am J Pathol 2020.
- 381 [7] Salazar E, Kuchipudi SV, Christensen PA, Eagar T, Yi X, Zhao P, Jin Z, Long SW, Olsen RJ, Chen
382 J, Castillo B, Leveque C, Towers D, Lavinder JJ, Gollihar J, Cardona JA, Ippolito GC, Nissly RH, Bird I,
383 Greenawalt D, Rossi RM, Gontu A, Srinivasan S, Poojary I, Cattadori IM, Hudson P, Josleyn NM,
384 Prugar L, Huie KE, Herbert AS, Bernard DW, Dye JM, Kapur V, Musser JM: Convalescent plasma anti-
385 SARS-CoV-2 spike protein ectodomain and receptor binding domain IgG correlate with virus
386 neutralization. J Clin Invest 2020.
- 387 [8] Barone P, DeSimone RA: Convalescent plasma to treat coronavirus disease 2019 (COVID-19):
388 considerations for clinical trial design. Transfusion 2020, 60:1123-7.
- 389 [9] Liu STH, Lin H-M, Baine I, Wajnberg A, Gumprecht JP, Rahman F, Rodriguez D, Tandon P, Bassily-
390 Marcus A, Bander J, Sanky C, Dupper A, Zheng A, Altman DR, Chen BK, Krammer F, Mendu DR,
391 Firpo-Betancourt A, Levin MA, Bagiella E, Casadevall A, Cordon-Cardo C, Jhang JS, Arinsburg SA,
392 Reich DL, Aberg JA, Bouvier NM: Convalescent plasma treatment of severe COVID-19: A matched
393 control study. medRxiv 2020:2020.05.20.20102236.
- 394 [10] Hastie T, Tibshirani R, Wainwright M: Statistical Learning with Sparsity: The Lasso and
395 Generalizations. Boca Raton, FL: CRC Press, 2015.
- 396 [11] Lasso SS: Stata Reference Manual: Release 16. 2020.
- 397 [12] Youden WJ: Index for rating diagnostic tests. Cancer 1950, 3:32-5.
- 398 [13] Eckhardt CM, Cummings MJ, Rajagopalan KN, Borden S, Bitan ZC, Wolf A, Kantor A, Briese T,
399 Meyer BJ, Jacobson SD, Scotto D, Mishra N, Philip NM, Stotler BA, Schwartz J, Shaz B, Spitalnik SL,
400 Eisenberger A, Hod EA, Justman J, Cheung K, Lipkin WI, O'Donnell MR: Evaluating the efficacy and
401 safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A
402 structured summary of a study protocol for a randomized controlled trial. Trials 2020, 21:499.
- 403 [14] Gharbharan A, Jordans CCE, GeurtsvanKessel C, den Hollander JG, Karim F, Mollema FPN,
404 Stalenhoef JE, Dofferhoff A, Ludwig I, Koster A, Hassing R-J, Bos JC, van Pottelberge GR, Vlasveld IN,

405 Ammerlaan HSM, Segarceanu E, Miedema J, van der Eerden M, Papageorgiou G, te Broekhorst P,
406 Swaneveld FH, Katsikis PD, Mueller Y, Okba NMA, Koopmans MPG, Haagmans BL, Rokx C, Rijnders
407 B: Convalescent Plasma for COVID-19. A randomized clinical trial. medRxiv
408 2020:2020.07.01.20139857.

409 [15] Hegerova L, Gooley T, Sweerus KA, Maree CL, Bailey N, Bailey M, Dunleavy V, Patel K, Alcorn K,
410 Haley NR, Johnsen JM, Konkle BA, Lahti AC, Alexander ML, Goldman JD, Lipke A, Lim SJ, Sullivan
411 MD, Pauk JS, Pagel JM: Use of Convalescent Plasma in Hospitalized Patients with Covid-19 - Case
412 Series. Blood 2020.

413 [16] Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, Kong Y, Ren L, Wei Q, Mei H, Hu C, Tao C, Yang
414 R, Wang J, Yu Y, Guo Y, Wu X, Xu Z, Zeng L, Xiong N, Chen L, Wang J, Man N, Liu Y, Xu H, Deng E,
415 Zhang X, Li C, Wang C, Su S, Zhang L, Wang J, Wu Y, Liu Z: Effect of Convalescent Plasma Therapy
416 on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A
417 Randomized Clinical Trial. JAMA 2020.

418 [17] Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P, Latha B, Bundas S,
419 Kumar V, Dosi R, Khambholja JK, de Souza R, Mesipogu RR, Srivastava S, Dube S, Chaudhary K, S
420 S, Mattuvar K SA, Rajendran V, Sundararajaperumal A, Balamanikandan P, Maheswari RSU, Jayanthi
421 R, Ragunathanan S, Bhandari S, Singh A, Pal A, Handa A, Rankawat G, Kargirwar K, Regi J, Rathod
422 D, Pathrose E, Bhutaka N, Patel MH, Verma RJ, Malukani K, Patel S, Thakur A, Joshi S, Kulkarni R,
423 Suthar NN, Shah NM, Purohit HM, Shah CK, Patel MN, Shah S, Shah SH, Memon T, Beriwalla VR,
424 Jashnani K, Ezzy F, Agrawal S, Bhadade R, N AM, Madke T, Kavishwar V, Waghmare R, Valvi N,
425 Chander BT, Sekhar AV, Maurya AK, Hemanth K, Nagamani K, Sudha K, Chandra TR, Rao KT,
426 Vyshnavi J, Upadhyay R, Bahadur S, Pathak R, Seth S, Gupta R, Saxena R, Dwivedi P, Malik R,
427 Chourasia D, Lalwani J, Sharma U, Marko J, Suri A, Kumar V, Kaushik R, Kodan P, Acharya BP, Gaur
428 KK, Gupta A, Sachdeva P, Dogra S, Jindal A, John MJ, Dhanju AS, Khetrepal R, Sharma N, Kukar N,
429 Kavita D, Kumar R, Mahajan R, Singh G, Kaur J, Singh RP, Bassi R, Parikh S, Shrivastav O, Shastri J,
430 Desai M, Udupa S, Bafna VA, Barge V, Madane R, Yadav S, Mishra S, Bajpayee A, Garg MK, Bohra
431 GK, Nag V, Anne PB, Nadeem M, Singh P, Niwas R, Khaire NS, Sharma R, Singh Mp, Sachdeva N,

432 Sachdev S, Hans R, Suri V, Yaddanapudi LN, Lakshmi P, Singh N, Bhushan D, Kumar N, Tambe M,
433 Salvi S, Kadgi N, Sangle S, Nakate L, Joshi S, Karyakarte R, Goyanka S, Sharma N, Verma N, Das A,
434 Bahl M, Wadhwa N, Bhat S, Deshmukh S, Wagh V, Kulkarni A, Yardi T, Kalgud RS, Reddy P, Yevoor
435 K, Gajula P, Maleyur V, S M, HN M, Gurtoo A, Sud R, Pahuja S, Prakash A, Gogoi P, Shukla S, Reddy
436 DH, Chandra T, Pandey S, Maurya P, Wahid A, Kumar V, Upadhyay K, Bhatnagar N, Shah N, Shah M,
437 Patel T, Jaiswal RM, Jain A, Sharma S, Rijhwani P, Gupta N, Patel TC, Solu MG, Patel J, Shah YR,
438 Jarag M, Godbole V, Shah M, Raj R, Nagori I, Jha PR, Shah AD, Yeeli G, Jain A, Gill RK, Babu KS,
439 Babu BS, Mohan A, Vengamma B, Sekhar KC, Damam S, Narsimhulu K, Aparna C, Baleswari G, K
440 RR, Chandrasekhar P, Panjwani SJ, Akholkar PJ, Joshi KP, Shah PH, Barvaliya M, Baldi M, Yadav A,
441 Gupta M, Rawat N, Chawda D, Natarajan M, Sintha M, Kumar DP, Rabbani F, Khadke VK, Patki D,
442 Marathe S, D Souza C, Tadha V, Arora S, Gupta DK, Dua S, Chauhan N, Chahar AS, Mammen JJ,
443 Kumar S, Daniel D, Singh R, Dhat V, Agarwal Y, Arora S, Pathak A, Purohit M, Sharma A, Sharma J,
444 Madkaikar M, Joshi K, Yadav RM, Bhagwat S, Karnik ND, Gokhale YA, Naik L, Margam S, Das S,
445 Turuk A, Kumar VS, Kanagasabai K, Sabarinathan R, Deshpande G, Sharma S, Gunjekar R, Shete A,
446 Phagiwala D, Patil C, Shingade S, Jarande K, Kaushal H, Yadav P, Sapkal G, Abraham P:
447 Convalescent plasma in the management of moderate COVID-19 in India: An open-label parallel-arm
448 phase II multicentre randomized controlled trial (PLACID Trial). medRxiv 2020:2020.09.03.20187252.
449 [18] Avendano-Sola C, Ramos-Martinez A, Munez-Rubio E, Ruiz-Antoran B, Malo de Molina R, Torres
450 F, Fernandez-Cruz A, Callejas-Diaz A, Calderon J, Payares-Herrera C, Salcedo I, Romera I, Lora-
451 Tamayo J, Mancheno-Losa M, Paciello ML, Villegas C, Estrada V, Saez-Serrano I, Porrás-Leal ML,
452 Jarilla-Fernandez MdC, Pano-Pardo JR, Moreno-Chulilla JA, Arrieta-Aldea I, Bosch A, Belhassen-
453 Garcia M, Lopez-Villar O, Ramos-Garrido A, Blanco L, Madrigal ME, Contreras E, Muniz-Diaz E,
454 Domingo-Morera JM, Casas-Flecha I, Perez-Olmeda M, Garcia-Perez J, Alcami J, Bueno JL, Duarte
455 RF: Convalescent Plasma for COVID-19: A multicenter, randomized clinical trial. medRxiv
456 2020:2020.08.26.20182444.
457 [19] Balcells ME, Rojas L, Le Corre N, Martínez-Valdebenito C, Ceballos ME, Ferrés M, Chang M,
458 Vizcaya C, Mondaca S, Huete Á, Castro R, Sarmiento M, Villarroel L, Pizarro A, Ross P, Santander J,

459 Lara B, Ferrada M, Vargas-Salas S, Beltrán-Pavez C, Soto-Rifo R, Valiente-Echeverría F, Caglevic C,
460 Mahave M, Selman C, Gazitúa R, Briones JL, Villarroel-Espindola F, Balmaceda C, Espinoza MA,
461 Pereira J, Nervi B: Early Anti-SARS-CoV-2 Convalescent Plasma in Patients Admitted for COVID-19: A
462 Randomized Phase II Clinical Trial. medRxiv 2020:2020.09.17.20196212.

463

464

465 **Figure legends**

466 **Figure 1.** Ortho VITROS IgG signal/cutoff (S/C) ratio versus optical density at dilution 1:50 for serum
467 samples for all convalescent plasma collections and for which parallel testing data was available
468 through September 27, 2020. The blue line is the linear regression line of best fit. Positive linear
469 correlation was significant ($R=0.88$; $P<0.001$). Red squares denote units transfused in the study. Black
470 circles denote samples for all other units collected and not transfused during the study. Many of these
471 units (black circles) were deferred due to the presence of donor HLA antibodies or positive donor
472 SARS-CoV-2 nasopharyngeal swab at the time of donation.

473
474 **Figure 2.** Flowchart of the study population. Propensity score matching was based on patient age
475 (categorical, per 10 years); sex; BMI (categorical, +/- 30); presence of diabetes, hypertension, chronic
476 pulmonary disease, chronic kidney disease, hyperlipidemia and/or coronary disease; baseline
477 ventilation status within 48 hrs of admission (room air, supplemental oxygen, and mechanical
478 ventilation); and use of any steroid, azithromycin, hydroxychloroquine, remdesivir, ribavirin, and
479 tocilizumab. After establishing the first propensity score-matched cohort and obtaining Day 0 for
480 controls, a second match was run between cases and controls based on the ventilation status at Day 0.

481
482 **Figure 3.** Kaplan-Meier curves for mortality within 60 days post-Day 0 for all patients who received
483 plasma with an anti-RBD IgG titer $\geq 1:1350$ regardless of time from admission (blue) propensity score-
484 matched to controls (red).

485
486 **Figure 4.** Kaplan-Meier curves for mortality within 60 days post-Day 0 for different cohorts of
487 propensity-score matched patients and controls. A) Patients transfused with plasma with an anti-RBD
488 IgG titer $\geq 1:1350$ and transfused within 72 hrs of admission (blue) propensity score-matched to control
489 patients (red). B) Patients transfused with plasma with an anti-RBD IgG titer $\geq 1:1350$ and intubated at
490 Day 0 (blue) propensity score-matched to control patients intubated at Day 0 (red). C) Patients
491 transfused with plasma with an anti-RBD IgG titer $< 1:1350$ (blue) propensity score-matched to control

492 patients (red). D) Patients transfused with plasma with an anti-RBD IgG titer $\geq 1:1350$ and transfused
493 greater than 72 hrs after admission (blue) propensity score-matched to control patients (red).

494

495 **Figure 5.** A) ROC curve with Youden index analysis for mortality within 60 days shown for all patients
496 transfused with COVID-19 convalescent plasma. Optimal cut point identified as 44 hours with an area
497 under the curve (AUC) of 0.62. Youden index was 0.23 with standard error of 0.0926. Sensitivity at cut
498 point was 0.75 with a specificity of 0.48. B) Kaplan-Meier curves for mortality within 60 days post-Day 0
499 for patients transfused with plasma with an anti-RBD IgG titer $\geq 1:1350$ within 44 hours after admission
500 (blue) propensity score-matched to control patients (red).

501

Figure 1




Figure 2






Figure 3




Number at risk	
Transfused	321 319 315 308 306 302 301
Not transfused	582 561 536 523 517 512 487

Figure 4


A



B



C



D





Figure 5

A



B




Table 1. Outcome Summary

	Propensity Score-Matched, Titer $\geq 1:1350$				
	Total (N=903)	Not Transfused (n=582)	Transfused (n=321)	Point estimate* (95% CI)	P-value
Disposition, 60 days					
Still admitted	11 (1.2)	6 (1.0)	5 (1.6)	0.71 (0.19, 2.56)	0.60
Discharge	799 (88.5)	503 (86.4)	296 (92.2)	(base outcome)	
Death	93 (10.3)	73 (12.5)	20 (6.2)	2.15 (1.30, 3.54)	0.003
Overall mortality within 28 days post-Day 0					
Alive	834 (92.4)	525 (90.2)	309 (96.3)	2.62 (1.46, 4.70)	0.001
Deceased	69 (7.6)	57 (9.8)	12 (3.7)		
Overall mortality within 60 days post-Day 0					
Alive	811 (89.8)	510 (87.6)	301 (93.8)	1.99 (1.25, 3.15)	0.004
Deceased	92 (10.2)	72 (12.4)	20 (6.2)		
Length of stay post-Day 0, median (IQR)	5.9 (3.1, 12.3)	5.9 (3.1, 12.9)	5.9 (3.2, 11.7)	-0.15 (-1.82, 1.52)	0.86
Required ICU post-Day 0					
No	607 (67.2)	392 (67.4)	215 (67.0)	0.99 (0.84, 1.16)	0.89
Yes	296 (32.8)	190 (32.6)	106 (33.0)		
ICU length of stay post-Day 0, mean (\pm SD)	12.0 (\pm 12.8)	11.6 (\pm 12.3)	12.7 (\pm 13.6)	-1.07 (-4.01, 1.88)	0.48
Mechanical ventilation requirement, post-Day 0					
No	752 (83.3)	477 (82.0)	275 (85.7)	1.26 (0.97, 1.63)	0.08
Yes	151 (16.7)	105 (18.0)	46 (14.3)		
Mechanical ventilation days post-Day 0 (only in patients who required ventilation), mean (\pm SD)	20.7 (\pm 19.8)	17.9 (\pm 16.2)	27.1 (\pm 25.4)	-9.15 (-16.91, -1.38)	0.02
Supplemental oxygen post-Day 0					
No	77 (8.5)	55 (9.5)	22 (6.9)	0.99 (0.99, 0.99)	<0.001
Yes	826 (91.5)	527 (90.5)	299 (93.1)		
Supplemental oxygen days post-Day 0 (in patients who required sup. oxygen), median (IQR)	6.4 (\pm 7.0)	6.5 (\pm 7.1)	6.3 (\pm 6.9)	0.23 (-0.65, 1.12)	0.61
Ventilation status at Day 0					
Room air	81 (9.0)	54 (9.3)	27 (8.4)	(base outcome)	

Low flow	549 (60.8)	353 (60.7)	196 (61.1)	0.90 (0.55, 1.48)	0.68
High flow/NIPPV	234 (25.9)	149 (25.6)	85 (26.5)	0.90 (0.53, 1.54)	0.70
Mechanical ventilation	36 (4.0)	24 (4.1)	12 (3.7)	0.87 (0.41, 1.83)	0.70
ECMO	3 (0.3)	2 (0.3)	1 (0.3)	0.52 (0.07, 3.89)	0.52
Death	0 (0.0)	0 (0.0)	0 (0.0)	--	--
Ventilation status at Day 7					
Room air	532 (58.9)	339 (58.2)	193 (60.1)	(base outcome)	
Low flow	105 (11.6)	63 (10.8)	42 (13.1)	0.85 (0.56, 1.31)	0.47
High flow/NIPPV	151 (16.7)	102 (17.5)	49 (15.3)	1.19 (0.85, 1.65)	0.31
Mechanical ventilation	95 (10.5)	62 (10.7)	33 (10.3)	1.07 (0.76, 1.51)	0.70
ECMO	6 (0.7)	4 (0.7)	2 (0.6)	1.14 (0.21, 6.26)	0.88
Death	14 (1.6)	12 (2.1)	2 (0.6)	3.42 (0.75, 15.52)	0.11
Ventilation status at Day 14					
Room air	696 (77.1)	435 (74.7)	261 (81.3)	(base outcome)	
Low flow	39 (4.3)	31 (5.3)	8 (2.5)	2.33 (1.11, 4.86)	0.03
High flow/NIPPV	40 (4.4)	23 (4.0)	17 (5.3)	0.81 (0.43, 1.52)	0.51
Mechanical ventilation	87 (9.6)	59 (10.1)	28 (8.7)	1.26 (0.84, 1.90)	0.26
ECMO	5 (0.6)	4 (0.7)	1 (0.3)	2.40 (0.27, 21.65)	0.44
Death	36 (4.0)	30 (5.2)	6 (1.9)	3.00 (1.22, 7.37)	0.02
Ventilation status at Day 28					
Room air	763 (84.5)	478 (82.1)	285 (88.8)	(base outcome)	
Low flow	13 (1.4)	9 (1.5)	4 (1.2)	1.34 (0.40, 4.44)	0.63
High flow/NIPPV	7 (0.8)	5 (0.9)	2 (0.6)	1.49 (0.29, 7.79)	0.64
Mechanical ventilation	47 (5.2)	30 (5.2)	17 (5.3)	1.05 (0.60, 1.84)	0.86
ECMO	4 (0.4)	3 (0.5)	1 (0.3)	1.79 (0.18, 17.34)	0.62
Death	69 (7.6)	57 (9.8)	12 (3.7)	2.83 (1.54, 5.22)	0.001
Ventilation status at Day 60					
Room air	797 (88.3)	501 (86.1)	296 (92.2)	(base outcome)	
Low flow	1 (0.1)	1 (0.2)	0 (0.0)	--	--
High flow/NIPPV	0 (0.0)	0 (0.0)	0 (0.0)	--	--
Mechanical ventilation	13 (1.4)	8 (1.4)	5 (1.6)	0.95 (0.29, 3.11)	0.93

ECMO Death	0 (0.0) 92 (10.2)	0 (0.0) 72 (12.4)	0 (0.0) 20 (6.2)	2.13 (1.29, 3.50)	0.003
Clinical improvement relative to Day 0 at Day 7					
No	364 (40.3)	249 (42.8)	115 (35.8)	0.89 (0.81, 0.98)	0.02
Yes	539 (59.7)	333 (57.2)	206 (64.2)		
Clinical improvement relative to Day 0 at Day 14					
No	209 (23.1)	154 (26.5)	55 (17.1)	0.89 (0.83, 0.95)	<0.001
Yes	694 (76.9)	428 (73.5)	266 (82.9)		
Clinical improvement relative to Day 0 at Day 28					
No	153 (16.9)	121 (20.8)	32 (10.0)	0.88 (0.83, 0.93)	<0.001
Yes	750 (83.1)	461 (79.2)	289 (90.0)		
Clinical improvement relative to Day 0 at Day 60					
No	125 (13.8)	100 (17.2)	25 (7.8)	0.90 (0.85, 0.94)	<0.001
Yes	778 (86.2)	482 (82.8)	296 (92.2)		
Interleukin-6 delta (Day 7-Day 0) (pg/mL), median (IQR)	42.5 (-40.5, 428.0)	20.0 (-53.0, 302.0)	56.0 (-18.0, 557.0)	-130.02 (-362.67, 102.63)	0.27
C-reactive protein delta (Day 7-Day 0) (mg/dL), median (IQR)	-9.2 (-17.8, -3.7)	-9.6 (-19.7, -4.0)	-8.5 (-16.3, -3.3)	-2.28 (-4.55, -0.01)	0.049
Ferritin delta (Day 7-Day 0) (ng/mL), median (IQR)	-11.5 (-322.5, 350.0)	-19.0 (-345.0, 314.0)	17.0 (-266.0, 361.0)	259.96 (-179.97, 699.88)	0.25
Fibrinogen delta (Day 7-Day 0) (mg/dL), median (IQR)	-164.0 (-342.0, -36.0)	-191.0 (-342.0, -57.0)	-136.5 (-339.0, -31.0)	-55.08 (-125.30, 15.13)	0.12
D-dimer delta (Day 7-Day 0) (µg/mL FEU), median (IQR)	0.2 (-0.3, 1.5)	0.1 (-0.4, 1.3)	0.4 (-0.2, 1.6)	-0.80 (-1.89, 0.30)	0.15

Values are in median (interquartile range, IQR) for continuous variables and number (%) for categorical variables.

*Point estimate obtained from generalized linear models (GLM) (for binary and continuous dependent variables) or multinomial logistic regression (for categorical dependent variables), which is risk ratio of outcome in non-transfusion versus transfusion (if categorical outcomes) or coefficient of outcome in non-transfusion versus transfusion (if continuous outcomes).

ECMO: extracorporeal membrane oxygenation; FEU: fibrinogen equivalent units; NIPPV: noninvasive positive pressure ventilation

Table 2. Univariate and Multivariate Cox Regression, Overall Mortality within 28 and 60 days, Controls Matched to Cases that Received Plasma with Titer $\geq 1:1350$

Univariate	Within 60 days			
	Alive (n=811)	Deceased (n=92)	Unadjusted HR (95% CI)	P-value
Convalescent plasma transfusion				
Transfused	301 (37.1)	20 (21.7)	(reference)	
Not Transfused	510 (62.9)	72 (78.3)	1.07 (1.05, 1.09)	<0.001
Age (years), median (IQR)	54.0 (44.0, 62.0)	65.0 (59.0, 76.0)	1.07 (1.05, 1.09)	<0.001
Age (years)				
<30	33 (4.1)	3 (3.3)	3.65 (0.66, 20.33)	0.14
30-39	111 (13.7)	3 (3.3)	1.14 (0.26, 5.02)	0.87
40-49	171 (21.1)	4 (4.3)	(reference)	
50-59	226 (27.9)	16 (17.4)	2.94 (0.97, 8.91)	0.06
60-69	182 (22.4)	30 (32.6)	6.54 (2.29, 18.72)	<0.001
70-79	69 (8.5)	20 (21.7)	10.85 (3.66, 32.19)	<0.001
≥ 80	19 (2.3)	16 (17.4)	29.06 (8.94, 94.50)	<0.001
Sex				
Female	362 (44.6)	33 (35.9)	(reference)	
Male	449 (55.4)	59 (64.1)	1.41 (0.92, 2.16)	0.12
Race				
White	530 (65.4)	65 (70.7)	(reference)	
Black	185 (22.8)	16 (17.4)	0.73 (0.43, 1.24)	0.25
Asian	41 (5.1)	5 (5.4)	1.02 (0.40, 2.58)	0.97
Other	25 (3.1)	5 (5.4)	1.53 (0.67, 3.49)	0.31
Unknown	30 (3.7)	1 (1.1)	0.28 (0.04, 2.07)	0.21
Ethnicity				
Non-Hispanic	399 (49.2)	48 (52.2)	(reference)	
Hispanic	406 (50.1)	42 (45.7)	0.86 (0.58, 1.26)	0.43
Unknown	6 (0.7)	2 (2.2)	2.52 (0.61, 10.53)	0.20
Body mass index (kg/m ²), median (IQR)	31.8 (27.8, 37.7)	30.1 (26.7, 34.7)	0.97 (0.94, 1.01)	0.10

Body mass index (kg/m ²)				
<18.5	2 (0.2)	0 (0.0)	--	--
18.5-24.9	88 (10.9)	11 (12.0)	(reference)	
25-29.9	220 (27.1)	32 (34.8)	1.17 (0.60, 2.28)	0.65
≥30	501 (61.8)	49 (53.3)	0.79 (0.41, 1.54)	0.49
Body mass index ≥30 (kg/m ²)				
<30	310 (38.2)	43 (46.7)	(reference)	
≥30	501 (61.8)	49 (53.3)	0.71 (0.46, 1.10)	0.12
Hypertension				
No	396 (48.8)	35 (38.0)	(reference)	
Yes	415 (51.2)	57 (62.0)	1.51 (0.98, 2.31)	0.06
Diabetes				
No	488 (60.2)	39 (42.4)	(reference)	
Yes	323 (39.8)	53 (57.6)	1.96 (1.30, 2.96)	0.001
Chronic pulmonary disease				
No	721 (88.9)	74 (80.4)	(reference)	
Yes	90 (11.1)	18 (19.6)	1.85 (1.12, 3.08)	0.02
Chronic kidney disease				
No	708 (87.3)	64 (69.6)	(reference)	
Yes	103 (12.7)	28 (30.4)	2.80 (1.79, 4.38)	<0.001
Hyperlipidemia				
No	541 (66.7)	48 (52.2)	(reference)	
Yes	270 (33.3)	44 (47.8)	1.79 (1.16, 2.76)	0.01
Coronary disease				
No	753 (92.8)	67 (72.8)	(reference)	
Yes	58 (7.2)	25 (27.2)	4.46 (2.77, 7.16)	<0.001
Baseline outcome group				
Room air	38 (4.7)	5 (5.4)	(reference)	
Supplemental oxygen	750 (92.5)	71 (77.2)	0.74 (0.30, 1.79)	0.50
Mechanical ventilation	23 (2.8)	16 (17.4)	4.33 (1.56, 12.04)	0.01
Ventilation status at Day 0				

Room air	78 (9.6)	3 (3.3)	(reference)	
Low flow	516 (63.6)	33 (35.9)	1.66 (0.53, 5.15)	0.38
High flow/NIPPV	194 (23.9)	40 (43.5)	4.99 (1.63, 15.25)	0.01
Mechanical ventilation	20 (2.5)	16 (17.4)	15.69 (4.74, 52.02)	<0.001
ECMO	3 (0.4)	0 (0.0)	--	--
ABO blood group				
A	204 (30.6)	25 (29.4)	0.91 (0.58, 1.42)	0.67
B	93 (14.0)	9 (10.6)	0.74 (0.36, 1.52)	0.42
AB	13 (2.0)	3 (3.5)	1.59 (0.52, 4.84)	0.42
O	356 (53.5)	48 (56.5)	(reference)	
Rh blood group				
Negative	54 (8.1)	11 (12.9)	(reference)	
Positive	612 (91.9)	74 (87.1)	0.62 (0.34, 1.15)	0.13
Interleukin-6 at baseline, (pg/mL), median (IQR) (n=604)	51.0 (23.0, 114.0)	106.0 (35.0, 309.0)	1.001 (1.00, 1.001)	<0.001
Interleukin-6 delta (Day 7-baseline), (pg/mL), median (IQR) (n=236)	26.0 (-51.0, 232.0)	496.0 (43.0, 966.0)	1.0004 (1.00, 1.001)	0.01
C-reactive protein at baseline, (mg/dL), median (IQR) (n=725)	9.7 (5.3, 16.4)	10.2 (6.2, 15.2)	0.99 (0.97, 1.02)	0.65
C-reactive protein delta (Day 7-baseline), (mg/dL), median (IQR) (n=403)	-9.5 (-18.3, -3.6)	-8.0 (-14.4, -4.3)	1.01 (0.99, 1.03)	0.30
Ferritin at baseline, (ng/mL), median (IQR) (n=726)	809.5 (427.0, 1565.0)	1160.5 (543.5, 1896.0)	1.00 (1.00, 1.00)	0.052
Ferritin delta (Day 7-baseline), (ng/mL), median (IQR) (n=396)	-20.5 (-351.0, 308.0)	141.5 (-272.0, 591.0)	1.0002 (1.00, 1.0003)	0.03
Fibrinogen at baseline, (mg/dL), median (IQR) (n=534)	658.0 (562.0, 749.0)	617.0 (526.0, 720.0)	0.99 (0.99, 1.00)	0.01
Fibrinogen delta (Day 7-baseline), (mg/dL), median (IQR) (n=155)	-178.0 (-347.5, -48.5)	-121.0 (-246.0, 49.0)	1.00 (1.00, 1.00)	0.37
D-dimer at baseline, (µg/mL FEU), median (IQR) (n=733)	0.9 (0.6, 1.5)	1.2 (0.7, 3.1)	1.12 (1.07, 1.16)	<0.001
D-dimer delta (Day 7-baseline), (µg/mL FEU), median (IQR) (n=394)	0.1 (-0.3, 1.0)	1.3 (0.1, 11.5)	1.08 (1.04, 1.12)	<0.001
Concomitant medication				

Any steroids	576 (71.0)	87 (94.6)	6.64 (2.72, 16.19)	<0.001
Dexamethasone	395 (48.7)	46 (50.0)	1.04 (0.67, 1.60)	0.87
Hydrocortisone	28 (3.5)	33 (35.9)	9.42 (6.12, 14.50)	<0.001
Methylprednisolone	297 (36.6)	67 (72.8)	4.21 (2.65, 6.67)	<0.001
Prednisone	109 (13.4)	23 (25.0)	1.96 (1.26, 3.04)	0.00
Azithromycin	596 (73.5)	68 (73.9)	1.01 (0.63, 1.60)	0.98
Hydroxychloroquine	80 (9.9)	12 (13.0)	1.37 (0.77, 2.42)	0.28
Lopinavir/ritonavir	7 (0.9)	2 (2.2)	2.32 (0.57, 9.46)	0.24
Remdesivir	306 (37.7)	34 (37.0)	0.95 (0.61, 1.49)	0.84
Ribavirin	27 (3.3)	4 (4.3)	1.33 (0.48, 3.66)	0.58
Tocilizumab	358 (44.1)	73 (79.3)	4.49 (2.70, 7.48)	<0.001
Multivariate	Within 28 days		Within 60 days	
	Adjusted HR (95% CI)	P-value	Adjusted HR (95% CI)	P-value
Convalescent plasma transfusion				
Transfused	(reference)		(reference)	
Not Transfused	1.94 (1.05, 3.58)	0.04	1.64 (1.00, 2.69)	0.049
Age (years)	1.06 (1.04, 1.09)	<0.001	1.09 (1.05, 1.13)	<0.001
Diabetes	1.69 (1.01, 2.84)	0.046	1.57 (1.02, 2.43)	0.04
Chronic kidney disease	1.44 (0.79, 2.60)	0.23	1.41 (0.83, 2.40)	0.20
Ventilation status at Day 0				
Room air	(reference)			
Low flow	3.42 (0.51, 23.12)	0.21	1.46 (0.49, 4.34)	0.50
High flow/NIPPV	5.14 (0.75, 35.13)	0.10	2.71 (0.96, 7.64)	0.06
Mechanical ventilation	12.99 (1.80, 93.62)	0.01	5.68 (1.91, 16.90)	0.002
ECMO	--	--	--	--
Any steroids	1.11 (1.03, 1.21)	0.01	1.06 (1.00, 1.13)	0.06
Tocilizumab	1.06 (1.01, 1.11)	0.01	1.04 (1.01, 1.06)	0.01
C-statistic	C-statistic = 0.87			C-statistic = 0.81

Values are in median (interquartile range, IQR) for continuous variables and number (%) for categorical variables.

Steroids and tocilizumab were treated as time-varying covariates in the multivariate model.

CI: confidence interval; HR: hazard ratio; ECMO: extracorporeal membrane oxygenation; FEU: fibrinogen equivalent units; NIPPV: noninvasive positive pressure ventilation

Table 3. Outcome summary, Propensity score-matched, Transfused with Plasma with Titer $\geq 1:1350$ within 44 hours of Admission

	Propensity score-matched, transfused ≤ 44 hrs, Titer ≥ 1350				
	Total (N=421)	Not Transfused (n=269)	Transfused (n=152)	Point estimate* (95% CI)	P-value
Disposition, 60 days					
Still admitted	4 (1.0)	1 (0.4)	3 (2.0)	0.20 (0.02, 2.00)	0.17
Discharge	377 (89.5)	234 (87.0)	143 (94.1)	(base outcome)	
Death	40 (9.5)	34 (12.6)	6 (3.9)	3.46 (1.40, 8.56)	0.01
Overall mortality with no time constraints					
Alive	381 (90.5)	235 (87.4)	146 (96.1)	3.20 (1.36, 7.54)	0.01
Deceased	40 (9.5)	34 (12.6)	6 (3.9)		
Overall mortality within 28 days post-Day 0					
Alive	390 (92.6)	243 (90.3)	147 (96.7)	2.94 (1.12, 7.74)	0.03
Deceased	31 (7.4)	26 (9.7)	5 (3.3)		
Overall mortality within 60 days post-Day 0					
Alive	382 (90.7)	236 (87.7)	146 (96.1)	3.11 (1.29, 7.50)	0.01
Deceased	39 (9.3)	33 (12.3)	6 (3.9)		
Length of Stay post-Day 0, median (IQR)	5.3 (2.9, 10.0)	5.0 (2.7, 10.0)	5.7 (3.5, 9.7)	-0.57 (-2.98, 1.85)	0.65
Required ICU post-Day 0					
No	291 (69.1)	183 (68.0)	108 (71.1)	1.10 (0.81, 1.50)	0.52
Yes	130 (30.9)	86 (32.0)	44 (28.9)		
ICU length of stay post-Day 0, mean (\pm SD)	10.8 (\pm 11.3)	10.7 (\pm 11.3)	11.2 (\pm 11.4)	-0.52 (-4.55, 3.50)	0.80
Mechanical ventilation requirement, post-Day 0					
No	347 (82.4)	217 (80.7)	130 (85.5)	1.34 (0.86, 2.08)	0.20
Yes	74 (17.6)	52 (19.3)	22 (14.5)		
Mechanical ventilation days post-Day 0 (for patients that required ventilation), mean (\pm SD)	19.8 (\pm 19.2)	17.9 (\pm 15.7)	24.2 (\pm 25.5)	-6.34 (-16.72, 4.03)	0.23
Supplemental oxygen post-Day 0					
No	60 (14.3)	50 (18.6)	10 (6.6)	0.79 (0.75, 0.84)	<0.001
Yes	361 (85.7)	219 (81.4)	142 (93.4)		

Supplemental oxygen days post-Day 0 (for patients that required sup. oxygen), median (IQR)	5.4 (±5.8)	5.6 (±6.4)	5.0 (±4.8)	0.60 (-0.55, 1.76)	0.31
Ventilation status at Day 7					
Room air	272 (64.6)	172 (63.9)	100 (65.8)	(base outcome)	
Low flow	38 (9.0)	19 (7.1)	19 (12.5)	0.58 (0.29, 1.15)	0.12
High flow/NIPPV	47 (11.2)	34 (12.6)	13 (8.6)	1.52 (0.77, 3.01)	0.23
Mechanical ventilation	52 (12.4)	35 (13.0)	17 (11.2)	1.20 (0.64, 2.25)	0.58
ECMO	4 (1.0)	2 (0.7)	2 (1.3)	0.58 (0.08, 4.22)	0.59
Death	8 (1.9)	7 (2.6)	1 (0.7)	4.07 (0.49, 33.99)	0.20
Ventilation status at Day 14					
Room air	346 (82.2)	214 (79.6)	132 (86.8)	(base outcome)	
Low flow	4 (1.0)	2 (0.7)	2 (1.3)	0.62 (0.09, 4.43)	0.63
High flow/NIPPV	13 (3.1)	10 (3.7)	3 (2.0)	2.06 (0.55, 7.69)	0.28
Mechanical ventilation	37 (8.8)	25 (9.3)	12 (7.9)	1.29 (0.62, 2.65)	0.50
ECMO	3 (0.7)	2 (0.7)	1 (0.7)	1.23 (0.11, 13.79)	0.87
Death	18 (4.3)	16 (5.9)	2 (1.3)	4.93 (1.09, 22.38)	0.04
Ventilation status at Day 28					
Room air	363 (86.2)	223 (82.9)	140 (92.1)	--	--
Low flow	4 (1.0)	4 (1.5)	0 (0.0)	--	--
High flow/NIPPV	3 (0.7)	3 (1.1)	0 (0.0)	--	--
Mechanical ventilation	18 (4.3)	12 (4.5)	6 (3.9)	--	--
ECMO	2 (0.5)	1 (0.4)	1 (0.7)	--	--
Death	31 (7.4)	26 (9.7)	5 (3.3)	--	--
Ventilation status at Day 60					
Room air	376 (89.3)	233 (86.6)	143 (94.1)	(base outcome)	
Low flow		0 (0.0)	0 (0.0)	--	--
High flow/NIPPV		0 (0.0)	0 (0.0)	--	--
Mechanical ventilation	6 (1.4)	3 (1.1)	3 (2.0)	0.61 (0.12, 3.10)	0.55
ECMO		0 (0.0)	0 (0.0)	--	--
Death	39 (9.3)	33 (12.3)	6 (3.9)	3.38 (1.33, 8.55)	0.01
Clinical Improvement relative to Day 0 at Day 7					

No	142 (33.7)	97 (36.1)	45 (29.6)	0.91 (0.79, 1.05)	0.19
Yes	279 (66.3)	172 (63.9)	107 (70.4)		
Clinical Improvement relative to Day 0 at Day 14					
No	81 (19.2)	62 (23.0)	19 (12.5)	0.76 (0.71, 0.82)	<0.001
Yes	340 (80.8)	207 (77.0)	133 (87.5)		
Clinical Improvement relative to Day 0 at Day 28					
No	65 (15.4)	53 (19.7)	12 (7.9)	0.87 (0.81, 0.94)	0.001
Yes	356 (84.6)	216 (80.3)	140 (92.1)		
Clinical Improvement relative to Day 0 at Day 60					
No	54 (12.8)	45 (16.7)	9 (5.9)	0.89 (0.83, 0.95)	<0.001
Yes	367 (87.2)	224 (83.3)	143 (94.1)		
Interleukin-6 delta (Day 7-Day 0), (pg/mL), median (IQR)	36.0 (-52.0, 370.0)	16.5 (-39.0, 336.0)	39.0 (-56.5, 531.0)	-151.40 (-591.29, 288.49)	0.50
C-reactive protein delta (Day 7-Day 0), (mg/dL), median (IQR)	-10.8 (-19.7, -5.0)	-10.8 (-22.3, -4.9)	-10.7 (-19.3, -5.3)	-0.09 (-3.90, 3.71)	0.96
Ferritin delta (Day 7-Day 0), (ng/mL), median (IQR)	-75.0 (-419.0, 192.0)	-110.0 (-468.0, 205.0)	-51.0 (-323.0, 189.0)	-29.53 (-376.08, 317.02)	0.87
Fibrinogen delta (Day 7-Day 0), (mg/dL), median (IQR)	-239.0 (-361.0, -74.5)	-140.0 (-321.5, -73.5)	-302.5 (-378.0, -82.5)	55.24 (-41.82, 152.29)	0.27
D-dimer delta (Day 7-Day 0), (µg/mL FEU), median (IQR)	0.4 (-0.3, 2.7)	0.4 (-0.2, 3.4)	0.3 (-0.3, 1.7)	1.13 (-0.50, 2.76)	0.18

Values are in median (interquartile range, IQR) for continuous variables and number and % for categorical variables

*Point estimate obtained from the generalized linear models (GLM, for binary and continuous dependent variables) or multinomial logistic regression (for categorical variables) which is risk ratio of outcome in non-transfusion versus transfusion (if categorical outcomes or coefficient of outcome in non-transfusion versus transfusion (if continuous outcomes)

CI: Confidence Interval ECMO: extracorporeal membrane oxygenation; FEU: fibrinogen equivalent units; NIPPV: noninvasive positive pressure ventilation

Table 4. Univariate and Multivariate Cox Regression, Overall Mortality within 28 and 60 days, Controls Matched to Cases that Received Plasma with Titer $\geq 1:1350$ within 44 hours of Hospital Admission

Univariate	Within 60 days			
	Alive (n=382)	Deceased (n=39)	Unadjusted HR (95% CI)	P-value
Convalescent plasma transfusion				
Transfused	146 (38.2)	6 (15.4)	(reference)	
Not Transfused	236 (61.8)	33 (84.6)	3.26 (1.32, 8.04)	0.01
Age (years), median (IQR)	51.0 (39.0, 60.0)	65.0 (59.0, 75.0)	1.08 (1.06, 1.11)	<0.001
Age (years)				
<30	28 (7.3)	1 (2.6)	1.47 (0.13, 16.32)	0.75
30-39	68 (17.8)	0 (0.0)	--	--
40-49	83 (21.7)	2 (5.1)	(reference)	
50-59	104 (27.2)	7 (17.9)	2.71 (0.56, 13.24)	0.22
60-69	73 (19.1)	15 (38.5)	7.80 (1.74, 34.96)	0.01
70-79	20 (5.2)	9 (23.1)	16.08 (3.38, 76.64)	<0.001
≥ 80	6 (1.6)	5 (12.8)	26.69 (5.03, 141.70)	<0.001
Sex				
Female	160 (41.9)	11 (28.2)	(reference)	
Male	222 (58.1)	28 (71.8)	1.76 (0.86, 3.59)	0.12
Race				
White	250 (65.4)	30 (76.9)	(reference)	
Black	78 (20.4)	5 (12.8)	0.55 (0.21, 1.42)	0.21
Asian	27 (7.1)	2 (5.1)	0.63 (0.15, 2.77)	0.54
Other	13 (3.4)	0 (0.0)	--	--
Unknown	14 (3.7)	2 (5.1)	1.18 (0.27, 5.09)	0.82
Ethnicity				
Non-Hispanic	176 (46.1)	20 (51.3)	(reference)	
Hispanic	201 (52.6)	19 (48.7)	0.83 (0.45, 1.53)	0.56
Unknown	5 (1.3)	0 (0.0)		

Body mass index (kg/m ²), median (IQR)	31.6 (28.3, 36.8)	30.2 (25.9, 33.6)	0.94 (0.89, 0.99)	0.02
Body mass index (kg/m ²)				
<18.5	1 (0.3)	0 (0.0)	--	--
18.5-24.9	30 (7.9)	7 (17.9)	(reference)	
25-29.9	114 (29.8)	12 (30.8)	0.47 (0.18, 1.24)	0.13
≥30	237 (62.0)	20 (51.3)	0.38 (0.17, 0.85)	0.02
Body mass index ≥30 (kg/m ²)				
<30	145 (38.0)	19 (48.7)	(reference)	
≥30	237 (62.0)	20 (51.3)	0.65 (0.36, 1.19)	0.17
Hypertension				
No	199 (52.1)	10 (25.6)	(reference)	
Yes	183 (47.9)	29 (74.4)	2.98 (1.41, 6.30)	0.004
Diabetes				
No	237 (62.0)	16 (41.0)	(reference)	
Yes	145 (38.0)	23 (59.0)	2.23 (1.26, 3.97)	0.01
Chronic pulmonary disease				
No	344 (90.1)	32 (82.1)	(reference)	
Yes	38 (9.9)	7 (17.9)	1.88 (0.84, 4.23)	0.13
Chronic kidney disease				
No	357 (93.5)	34 (87.2)	(reference)	
Yes	25 (6.5)	5 (12.8)	1.93 (0.80, 4.67)	0.15
Hyperlipidemia				
No	281 (73.6)	21 (53.8)	(reference)	
Yes	101 (26.4)	18 (46.2)	2.26 (1.19, 4.29)	0.01
Coronary disease				
No	367 (96.1)	36 (92.3)	(reference)	
Yes	15 (3.9)	3 (7.7)	2.00 (0.60, 6.59)	0.26
Baseline outcome group				
Room air	12 (3.1)	1 (2.6)	(reference)	
Supplemental oxygen	343 (89.8)	24 (61.5)	0.83 (0.10, 6.52)	0.86

Mechanical ventilation	27 (7.1)	14 (35.9)	5.03 (0.69, 36.51)	0.11
Ventilation status at Day 0				
Room air	33 (8.6)	1 (2.6)	(reference)	
Low flow	248 (64.9)	8 (20.5)	1.05 (0.14, 8.10)	0.97
High flow/NIPPV	72 (18.8)	17 (43.6)	7.01 (0.96, 51.32)	0.06
Mechanical ventilation	27 (7.1)	13 (33.3)	12.98 (1.92, 87.59)	0.01
ECMO	2 (0.5)	0 (0.0)	--	--
ABO blood group				
A	82 (26.1)	11 (29.7)	1.16 (0.58, 2.34)	0.68
B	43 (13.7)	4 (10.8)	0.83 (0.28, 2.48)	0.74
AB	9 (2.9)	1 (2.7)	0.95 (0.13, 6.95)	0.96
O	180 (57.3)	21 (56.8)	(reference)	
Rh blood group				
Negative	31 (9.9)	7 (18.9)	(reference)	
Positive	283 (90.1)	30 (81.1)	0.50 (0.24, 1.08)	0.08
Interleukin-6 at baseline, (pg/mL), median (IQR) (n=316)	57.0 (25.0, 116.5)	85.5 (52.0, 192.5)	1.001 (1.00, 1.001)	<0.001
Interleukin-6 delta (Day 7-baseline), (pg/mL), median (IQR) (n=98)	3.5 (-52.0, 296.0)	323.5 (-12.5, 1101.5)	1.00 (1.00, 1.00)	0.65
C-reactive protein at baseline, (mg/dL), median (IQR) (n=353)	9.7 (5.6, 16.6)	12.7 (5.5, 19.1)	1.02 (0.98, 1.05)	0.31
C-reactive protein delta (Day 7-baseline), (mg/dL), median (IQR) (n=169)	-10.9 (-19.7, -5.4)	-7.0 (-20.2, -4.3)	1.00 (0.97, 1.03)	0.92
Ferritin at baseline, (ng/mL), median (IQR) (n=358)	791.0 (375.0, 1462.0)	1408.0 (509.0, 2152.0)	1.0001 (1.00, 1.0001)	<0.001
Ferritin delta (Day 7-baseline), (ng/mL), median (IQR) (n=163)	-77.0 (-438.0, 174.0)	-66.0 (-322.0, 314.0)	1.00 (1.00, 1.00)	0.11
Fibrinogen at baseline, (mg/dL), median (IQR) (n=287)	643.0 (535.0, 748.0)	637.0 (589.0, 712.0)	1.00 (0.99, 1.00)	0.23
Fibrinogen delta (Day 7-baseline), (mg/dL), median (IQR) (n=60)	-191.0 (-360.0, -69.0)	-248.0 (-477.0, -141.0)	1.00 (1.00, 1.00)	0.22

D-dimer at baseline, (µg/mL FEU), median (IQR) (n=364)	0.9 (0.6, 1.7)	2.0 (0.8, 4.3)	1.15 (1.10, 1.21)	<0.001
D-dimer delta (Day 7-baseline), (µg/mL FEU), median (IQR) (n=174)	0.2 (-0.3, 1.6)	3.2 (0.7, 13.6)	1.08 (1.04, 1.14)	0.001
Concomitant medication				
Any steroids	232 (60.7)	37 (94.9)	11.03 (2.69, 45.28)	0.001
Dexamethasone	129 (33.8)	16 (41.0)	1.34 (0.67, 2.67)	0.41
Hydrocortisone	9 (2.4)	16 (41.0)	13.97 (7.70, 25.35)	<0.001
Methylprednisolone	143 (37.4)	28 (71.8)	3.85 (1.84, 8.09)	<0.001
Prednisone	26 (6.8)	4 (10.3)	1.48 (0.54, 4.06)	0.44
Azithromycin	265 (69.4)	30 (76.9)	1.41 (0.69, 2.86)	0.35
Hydroxychloroquine	35 (9.2)	3 (7.7)	0.83 (0.25, 2.74)	0.76
Lopinavir/ritonavir	1 (0.3)	0 (0.0)	--	--
Remdesivir	155 (40.6)	15 (38.5)	0.91 (0.47, 1.79)	0.79
Ribavirin	4 (1.0)	0 (0.0)	--	--
Tocilizumab	158 (41.4)	31 (79.5)	5.01 (2.35, 10.68)	<0.001
Multivariate (n=421)	Within 28 days		Within 60 days	
	Adjusted HR (95% CI)	P-value	Adjusted HR (95% CI)	P-value
Convalescent plasma transfusion				
Transfused	(reference)		(reference)	
Not Transfused	2.63 (1.04, 6.64)	0.04	2.90 (1.22, 6.94)	0.02
Age (years)	1.09 (1.06, 1.13)	<0.001	1.08 (1.05, 1.12)	<0.001
Diabetes	1.74 (0.90, 3.38)	0.10	1.87 (1.04, 3.36)	0.04
Any steroid	8.45 (1.78, 40.03)	0.01	11.16 (2.54, 48.99)	0.001
C-statistic	C-statistic = 0.86	--	C-statistic = 0.86	--

Values are in median (interquartile range, IQR) for continuous variables and number (%) for categorical variables.

Steroids and tocilizumab were treated as time-varying covariates in the multivariate model.

CI: confidence interval; HR: hazard ratio; ECMO: extracorporeal membrane oxygenation; FEU: fibrinogen equivalent units; NIPPV: noninvasive positive pressure ventilation